2026/0159 - Invitation to Submit Proposals under Framework Agreements 961/2024 - Various Medicines, 2025/1627 - Cardiovascular System Medicines, 900/2024 - Antiretroviral Medicines for HIV Treatment, 899/2024 - Respiratory System Medicines, 780/2024 – Musculoskeletal System Medicines, used in the treatment of endocrine diseases and hormones, 491/2023 - Oncological and Immunomodulatory Medicines, 492/2023 - Anti-infective Medicines

This tender, identified as 2026/0159, is an invitation for proposals to supply a wide range of pharmaceutical products under several existing framework agreements. These agreements cover diverse categories of medicines, including general 'Various Medicines' (961/2024), medications for the cardiovascular system (2025/1627), antiretroviral drugs for HIV treatment (900/2024), respiratory system medications (899/2024), musculoskeletal system drugs, and those used for endocrine diseases and hormone therapies (780/2024). Additionally, the procurement includes oncological and immunomodulatory medicines (491/2023) and anti-infective agents (492/2023). Healthcare providers or relevant public entities are invited to submit proposals for the supply of these essential medicines. The tender aims to ensure a consistent and reliable supply chain for these critical pharmaceuticals, leveraging pre-established framework agreements to streamline the procurement process. Detailed specifications for each drug category and submission requirements are provided within the tender documents.

This is a supplies contract in the health and medical services and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 9.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.